Whereas the CD34 CE was significantly different with the AS104 and the Spectra, the CD34 CE of both machines correlated inversely with peripheral blood CD34+ cell counts, showing a significant decline with increasing numbers of circulating CD34+ cells. Nevertheless, at > or 40 preapheresis CD34+ cells per microL, sufficient hematopoietic autografts of > or =2.5 x 10(6) CD34+ cells per kg were harvested by a single conventional-volume (11 L) leukapheresis on both cell separators.

No abstract

Summary:Between October 1989 and February 1997, 13 patients with refractory or relapsed seminomas were treated with high-dose chemotherapy (HDCT) as part of consecutive phase I/II studies. Six patients had failed prior cisplatin-based first-line treatments and seven patients had also failed cisplatin-based salvage treatments. After The majority of seminoma patients presenting with stage I or nonbulky stage II disease will be cured by orchiectomy with or without retroperitoneal radiotherapy. 1 Only patients with bulky stage II or stage III seminomas are treated with three to four cycles of cisplatin-based combination regimens identical to the ones used in metastatic non-seminomatous germ cell tumors (NSGCT). 1,2 Cisplatin-based firstline chemotherapy will cure 86% of patients in the good prognosis and 72% of patients in the intermediate prognosis category according to the IGCCCG classification. 3 The optimal salvage strategy in seminoma patients who fail cisplatin-based first-line treatment is unknown. Further conventional-dose chemotherapy as well as high-dose chemotherapy (HDCT) are both highly effective, but HDCT is more toxic and might possibly be delayed for second or subsequent salvage attempts. [4][5][6]